Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients
Open Access
- 22 October 2012
- journal article
- research article
- Published by SAGE Publications in Diabetes and Vascular Disease Research
- Vol. 10 (3), 239-245
- https://doi.org/10.1177/1479164112460253
Abstract
Serum soluble receptor for advanced glycation end product (sRAGE) may reflect the activity of the advanced glycation end product (AGE)–receptor for advanced glycation end product (RAGE) axis, which has been proposed as a potential mechanism linking hyperglycaemia to vascular complications in diabetes. We have investigated whether serum AGEs, sRAGE and pentosidine levels were increased and correlated with microvascular complications in type 2 diabetes mellitus (DM). We included 30 healthy control subjects, and 200 diabetic patients were divided into two subgroups: 100 patients with diabetic retinopathy and 100 patients with diabetic nephropathy. AGEs, sRAGE and pentosidine were measured in serum by enzyme-linked immunosorbent assay (ELISA). Serum AGEs, sRAGE and pentosidine levels were significantly increased in diabetic patients with retinopathy and in diabetic patients with nephropathy compared to control subjects (p < 0.001). Serum AGEs, sRAGE and pentosidine levels are positively associated with microvascular complications in type 2 DM. Multiple regression analysis reveals serum pentosidine as an independent determinant of the presence of diabetic retinopathy (p = 0.004) and the presence of hypertension (p = 0.018) and hyperlipidaemia (p = 0.036). Pentosidine levels may be a biomarker for microvascular complications in type 2 diabetic patients.This publication has 35 references indexed in Scilit:
- Pentosidine and N-Carboxymethyl-Lysine: Biomarkers for Type 2 Diabetic RetinopathyEuropean Journal of Ophthalmology, 2010
- Involvement of Toxic AGEs (TAGE) in the Pathogenesis of Diabetic Vascular Complications and Alzheimer's DiseaseJournal of Alzheimer's Disease, 2009
- The Role of Advanced Glycation End Products in Progression and Complications of DiabetesJournal of Clinical Endocrinology & Metabolism, 2008
- Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic StrategyCurrent Pharmaceutical Design, 2005
- Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settingsAdvanced Drug Delivery Reviews, 2002
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Advanced glycation: an important pathological event in diabetic and age related ocular diseaseBritish Journal of Ophthalmology, 2001
- Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end productJournal of the American Society of Nephrology, 1998
- Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatmentKidney International, 1996
- Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry.Journal of Histochemistry & Cytochemistry, 1995